June 19, 2025 – The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections. Originally approved in 2012 as a treatment for people with HIV that no longer responded to ...

Miguel, a 63-year-old Los Angeles teacher, recently marked the 38th anniversary of his diagnosis with HIV. The doctor had told him he would be dead in a couple of years. He lived fearful that each ...

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option ...

Forbes contributors publish independent expert analyses and insights. Dr. Omer Awan is a practicing physician who covers public health. A twice-yearly injection of a drug known as lenacapavir offered ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV. Gilead Sciences, maker of the drug, ...

Dolutegravir plus lamivudine demonstrates noninferiority to the standard-of-care three-drug regimen in treatment-naive patients with HIV without preliminary drug resistance testing. Researchers ...

Gilead Sciences, Inc. GILD has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. Biktarvy ...

Sofosbuvir, a hepatitis C treatment drug, can adversely interact with tenofovir disoproxil, a HIV treatment drug, according to research led by Bingfang Yan, PhD, professor of biomedical and ...

UVA Health researchers say drugs used to treat HIV could help prevent a million new cases of Alzheimer’s each year – and they want clinical trials to find out. UVA’s Dr. Jayakrishna Ambati and his ...

Activities staff member Robert Hardrick teaches chair tai chi for residents of Broadway House for Continuing Care in New Jersey. (Photo: Courtesy of Broadway House) Nursing home patients with HIV may ...

Nearly 7% of people living with diabetes develop diabetic macular edema, a serious eye condition that can lead to vision loss, according to the Cleveland Clinic. Treatment can be costly, with the ...